Under the Public Health (Medicinal Cannabis) Act 2016 (PHMCA), a patient-class prescriber is defined as a specialist health practitioner, or a registrar (under the supervision of a specialist), in the specialities of:
- palliative medicine
- general paediatricians
- gynaecological oncologists
- haematologist physicians
- medical oncologists
- paediatric medical oncologists
- paediatric neurologists
- paediatric palliative medicine physicians
- radiation oncologists.
To be a patient–class prescriber you must:
- be a specialist medical practitioner, as specified in the PHMCA, and be listed with Queensland Health as a patient-class prescriber
- be registered (without undertakings on your registration) with the Australian Health Practitioners Regulation Agency
- have an established treating relationship with the patient
- be in direct communication with another medical practitioner who has an established long-term treating relationship with the patient and both are in well-documented agreement with the application for medicinal cannabis approval for therapeutic purposes.
Guidance and regulations
- Clinical guidance for the use of medicinal cannabis products, March 2017 (PDF 492 kB): covers the medical conditions/symptoms and products to be used.
- Medicinal cannabis access and use in Queensland, March 2017 (PDF 470 kB): the process for medical practitioners to access, prescribe and supply medicinal cannabis in Queensland.
- Standard for security of medicinal cannabis stock, January 2017 (PDF 326 kB): how to secure and store medicinal cannabis products, under Part 8 of the regulation.
- Public Health (Medicinal Cannabis) Regulation 2017 (PDF, 593KB) describes patient-class prescribers, the class of patients to be treated, and the medicinal cannabis products to be prescribed.
Forms and templates
- Treatment report (PDF 83 kB)
- Notification that treatment has commenced (PDF 67 kB)
- Notification of medicinal cannabis management plan (PDF 136 kB)
- Medicinal cannabis management plan (PDF 133 kB)
The patient-class prescriber must:
- notify Queensland Health prior to commencing treating patients with the specified medicinal cannabis product
- comply with the requirements of the PHMCA and regulation
- obtain informed written consent for the treatment of the patient with the medicinal cannabis product (s) and retain a copy on the patient record
- obtain a written driving acknowledgement from the patient advising the patient that they are not able to drive if they are taking THC based medicinal cannabis products and retain a copy on the patient record
- ensure the medicinal cannabis product is stored in accordance with the manufacturers specifications and meets the requirements of the security standard if they are dispensing the medication from their practice
- prepare a medicinal cannabis management plan (if the prescriber is supplying/dispensing from their practice) under the medicinal cannabis approval
- notify Queensland Health when a medicinal cannabis management plan is made
- notify Queensland Health when a patient has commenced treatment with a specified medicinal cannabis product
- provide a treatment report to the chief executive at 3 monthly intervals
- comply with any conditions imposed on a TGA approval relating to the medicinal cannabis product (s) being used